Video Player

Media error: Format(s) not supported or source(s) not found

Download File: https://player.vimeo.com/progressive_redirect/playback/1053815678/rendition/1080p/file.mp4?loc=external&signature=484557b8f39f1311e13772c34d7a7bce1ae5017b20be9651a5727f8aaa61f8e2

00:00

00:00

00:00

Use Up/Down Arrow keys to increase or decrease volume.

Our Mission

Pipeline

Our Focus

We are advancing a wholly owned portfolio of oral small molecule GPCR-targeted programs focused initially on treating patients with significant unmet needs in endocrinology, immunology and inflammation, and metabolic disease.

For each program, we utilize our Native Complex Platform™ to discover a diverse portfolio of small molecules with mechanisms of action designed to have disease-modifying potential and with distinct chemical properties. We have prioritized programs that offer biomarker-driven strategies for early clinical readouts.

Pipeline

Scroll sideways to view more.

Program

Development Status

Program / Target

Mode of Action

Therapeutic Area

Indications

Discovery

IND-enabling

Phase 1

Phase 2

Phase 3

PTH1R Program

Agonist

EndocrinologyOral Small Molecule PTH1R Agonist for Hypoparathyroidism

22%

SEP-631 (MRGPRX2)

Negative Allosteric Modulator

Immunology and InflammationOral Small Molecule MRGPRX2 NAM for CSU and Other Mast Cell Diseases

30%

TSHR Program

Negative Allosteric Modulator

EndocrinologyOral Small Molecule TSHR NAM for Graves’ Disease and TED

15%

GLP-1R, GIPR, GCGR Program

Single- and Multi-Agonists

Metabolic DiseasesObesity, T2D and other metabolic diseases

15%

No results found.

Other Therapeutic Areas of Interest / Focus:

Neurology, Women’s Health, Cardiovascular Disease and Respiratory Disease

PTH1R = Parathyroid Hormone 1 Receptor
TSHR = Thyroid-Stimulating Hormone Receptor
MRGPRX2 = MAS-Related G Protein-Coupled Receptor X2
GLP-1R = Glucagon-Like Peptide 1 Receptor.
GIPR = Gastric Inhibitory Polypeptide Receptor
GCGR = Glucagon Receptor

The Details

Programs
Additional Information

PTH1R Program

PTH1R Program

Oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism that could offer a convenient, functional replacement for PTH for all hypoparathyroidism patients.

SEP-631 (MRGPRX2)

SEP-631 (MRGPRX2)

Negative Allosteric Modulator

Oral small molecule negative allosteric modulator (NAM) that inhibits MRGPRX2 and could provide a differentiated treatment option for patients with chronic spontaneous urticaria (CSU) and other mast cell driven diseases.

TSHR Program

TSHR Program

Negative Allosteric Modulator

Oral small molecule thyroid-stimulating hormone receptor (TSHR) NAM that could offer a novel disease-modifying treatment approach for both Graves’ Disease and Thyroid Eye Disease.

GLP-1R, GIPR, GCGR Program

GLP-1R, GIPR, GCGR Program

Single- and Multi-Agonists

Novel, next-generation, oral small molecule single- or multi-acting agonists of the GLP-1, GIPR, glucagon receptors for patients with obesity, diabetes and other metabolic diseases.

No results found.

The Details

Publications